Community-Acquired Pneumonia in Children: Current Approaches to the Duration of Antibiotic Therapy

S.O. Mokiia-Serbina, T.V. Litvinova, H.O. Plokhinov

Abstract


Antibiotic therapy is recognized as the only scientifically valid method for the treatment of pneumonia, the outcome of which depends on proper antibiotic and the optimal duration of its administration that ensures the achievement of microbial eradication. The article discusses the duration of antibiotic therapy in uncomplicated community-acquired pneumonia in children. There was a trend to a reduction in the duration of antibiotic use, even with severe cases of the disease course. It is shown that currently there is no serious evidence base that would reliably show the enough duration of 5-day course of antibiotic therapy. It is proposed to consider 7–10 day course of treatment as the optimal duration of effective therapy for uncomplicated pneumonia. Implementation of the concept of short courses of antibiotic therapy is possible only under the supervision of the procalcitonin level.


Keywords


children; antibiotic therapy; uncomplicated community-acquired pneumonia

References


Baranov A.A. Clinical guidelines for diagnostics and treatment of acute respiratory diseases; treatment of pneumonia in children [Internet]. 2014 [cited 2016 Feb 16]. Available from: http://static-2.rosminzdrav.ru/system/attachments/attaches/000/018/677/ original. Russian

Community-acquired pneumonia in children: prevalence, diagnostics, treatment and prophylaxis. 1st ed., Nauchno-prakticheskaya programma. M: 2011. 63 p. Russian

Zaplatnikov A.L., Koroid N.V., Girina A.N., Neyman I.V. Principles of antibiotic therapy of community-acquired infections of respiratory tract in children. VSP. 2012;(2):22-29. Russian

Petchenko A.I., Luchaninova V.N., Knyish S.V., Shemetova E.V. Age features of community-acquired pneumonia in children. Fundamentalnyie issledovaniya. 2014;(2):141-145. Russian

Baranov A, Strachunskogo L. Using of antibiotics in children in outpatient practice. KMAH. 2007;9(3):200–210. Russian

Resolution of the round table participants on rational antimicrobial therapy of common diseases of children on February 24, 2010 (Kiev). Dityachiy lIkar. 2010;(2):13—15. Russian

Sinopalnikov A. Short-course antimicrobial chemotherapy: new paradigm of treatment of patients with community-acquired pneumonia? Klinicheskaya mikrobiologiya i antimikrobnaya himioterapiya. 2013;(2):86–95. Ukrainian

Strachunskiy L, Kozlov S, Belousov Y. Guideline on antiinfectious chemotherapy. Smolensk: MAKMAH; 2007. p. 464. Russian

Shihnebiev D. Current antimicrobial therapy of community-acquired pneumonia (a review). Mezhdunarodnyiy zhurnal prikladnyih i fundamentalnyih issledovaniy. 2014;(4):101-104. Russian

Levina A.S., Babachenko I.V., Sharipova E.V. Age-related etiologic characteristic of community-acquired pneumonia in children. Pulmonologiya. 2014;(5):62–66. Russian

Adkins B., C. LeClerc, and S. Marshall-Clarke. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 2004; 4: 553-564. doi:10.1038/nri1394

Aliberti S, Blasi F. Clinical Stability versus Clinical Failure in Patients with Community-Acquired Pneumonia. Semin Resp Crit Care Med. 2012;(33):284-291. PMID:22718214

Hazir T, Fox LM, Nisar YB, Fox MP, Ashraf YP et al. (2008) Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet 371: 49–56. doi:10.1016/S0140-6736(08)60071-9

Esposito S, Bosis S, Cavagna R, et al. Characteristics of Streptococcus pneumoniae and Atipical Bacterial Infections in Children 2-5 Years of Age with Community-Acquired Pneumoniae. Clinical Infectious Diseases. 2002; 35: 1345–1352. doi: 10.1086/344191

Bartlett J.G., Breiman R.F., Mandell L.A., et al. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26:811-38. doi: 10.1086/513953

Niederman M.S., Mandell L.A., Anzueto A. et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention. Am J Respir Crit Care Med 2001; 163:1730-54. doi: 10.1164/ajrccm.163.7.at1010

Havey T.C., Fowler R.A., Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care. 2011; 15(6): R267. doi: 10.1186/cc10545

Christ-Crain M., Stoltz D., Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174:84-93. doi: 10.1164/rccm.200512-1922OC

Greenberg D, Givon-Lavi N, Sadaka Y. et al. Short-course Antibiotic Treatment for Community-acquired Alveolar Pneumonia in Ambulatory Children: A Double-blind, Randomized, Placebo-controlled Trial. Pediatr Infect Dis J. 2014;33(2):136–142. doi: 10.1097/INF.0000000000000023

Bradley G, Byington C, Shah S. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):25–76. doi: 10.1093/cid/cir531

Mandell L.A., Bartlett J.G., Dowell S.F. et al. Update of practice guidelines for the management of communityacquired pneumonia in immunocompetent adults. Clin Inf Dis 2003; 37:1405-33. doi: 10.1086/380488




DOI: https://doi.org/10.22141/2224-0551.2.70.2016.73837

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru